van Delft Frederik, Koffijberg Hendrik, Retèl Valesca, Heuvel Michel van den, IJzerman Maarten
Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Hallenweg 5, 7522 NH Enschede, The Netherlands.
Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Cancers (Basel). 2020 Apr 30;12(5):1120. doi: 10.3390/cancers12051120.
With the introduction of targeted therapies and immunotherapy, molecular diagnostics gained a more profound role in the management of non-small cell lung cancer (NSCLC). This study aimed to systematically search for studies reporting on the use of liquid biopsies (LB), the correlation between LBs and tissue biopsies, and finally the predictive value in the management of NSCLC. A systematic literature search was performed, including results published after 1 January 2014. Articles studying the predictive value or validity of a LB were included. The search (up to 1 September 2019) retrieved 1704 articles, 1323 articles were excluded after title and abstract screening. Remaining articles were assessed for eligibility by full-text review. After full-text review, 64 articles investigating the predictive value and 78 articles describing the validity were included. The majority of studies investigated the predictive value of LBs in relation to therapies targeting the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) receptor (n = 38). Of studies describing the validity of a biomarker, 55 articles report on one or more EGFR mutations. Although a variety of blood-based biomarkers are currently under investigation, most studies evaluated the validity of LBs to determine EGFR mutation status and the subsequent targeting of EGFR tyrosine kinase inhibitors based on the mutation status found in LBs of NSCLC patients.
随着靶向治疗和免疫治疗的引入，分子诊断在非小细胞肺癌（NSCLC）的管理中发挥了更重要的作用。本研究旨在系统检索报告液体活检（LB）的使用、LB与组织活检之间的相关性以及最终在NSCLC管理中的预测价值的研究。进行了系统的文献检索，包括2014年1月1日之后发表的结果。纳入研究LB预测价值或有效性的文章。检索（截至2019年9月1日）共检索到1704篇文章，经标题和摘要筛选后排除1323篇文章。对其余文章进行全文审查以评估其合格性。全文审查后，纳入64篇研究预测价值的文章和78篇描述有效性的文章。大多数研究调查了LB与靶向表皮生长因子受体（EGFR）或间变性淋巴瘤激酶（ALK）受体的治疗相关的预测价值（n = 38）。在描述生物标志物有效性的研究中，55篇文章报告了一种或多种EGFR突变。尽管目前正在研究多种基于血液的生物标志物，但大多数研究评估了LB确定EGFR突变状态的有效性以及随后根据NSCLC患者LB中发现的突变状态靶向EGFR酪氨酸激酶抑制剂的情况。
